![4d Pharma Plc](https://directorstalk.net/wp-content/uploads/2016/09/4d-pharma-plc.png)
4D Pharma PLC Annual Report and Notice of AGM
4D Pharma PLC (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announced today that the Annual Report and Accounts for the year to 31 December 2016 and
4D Pharma PLC (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announced today that the Annual Report and Accounts for the year to 31 December 2016 and
4D pharma PLC (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, has today announced the final results for the Company and its subsidiaries (together “the Group”)
4D pharma PLC (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announces that it has with immediate effect appointed Investec Bank plc as its joint corporate broker,
Owlstone Medical, a diagnostics company developing a breathalyzer for disease, today announced it has signed a master service agreement with 4D Pharma plc (AIM:DDDD), a pharmaceutical company focusing on the
Zeus Capital’s Dr Gary Waanders discusses live biotherapeutics, what’s driving the interest in this field, the key themes for how the LBP’s will work and the companies to look out for including 4D Pharma PLC in this exclusive interview with DirectorsTalk
The new age of live-biotherapeutics is the topic of conversation when Dr Gary Waanders, Healthcare Research Director at Zeus Capital talks to DirectorsTalk. Gary explains what is driving the interest
4D pharma plc (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, yesterday provided the following update on the development and first clinical trial of its proprietary diagnostic
Dr. Alex Stevenson, 4D’s LON:DDDD Chief Scientific Officer, commented: “Reduction in the stability and diversity of the microbiome is a recognised aspect of IBS pathophysiology. These results demonstrate that Blautix,
Niall Pearson a Corporate Broker at Hybridan chats with DirectorsTalk about the Biotech Sector. Niall provides some valuable insight into the Biotech Sector, explains the valuation gap and provides his